
























An	estimated	10–20%	of	all	patients	with	SLE	develop	clinical	disease	before	the	age	of	16	years	and	are	therefore	classified	as	childhood-onset	or	 juvenile-onset	SLE	(jSLE)	[7,8].	Peak	disease	onset	 in	the	 jSLE	cohort	 is
between	12	and	14	years.	Patients	with	disease	onset	before	5	years	of	age	are	very	uncommon	and	may	be	referred	to	as	early-onset	SLE	(eoSLE)	[9,10].	Of	note,	jSLE,	particularly	eoSLE	cases,	is	characterised	by	more	severe	clinical


























































































monogenic	 forms	 of	 SLE	 will	 (at	 least	 initially)	 not	 present	 with	 high	 titres	 of	 autoantibodies	 and	 may	 not	 exhibit	 autoreactive	 lymphocyte	 populations.	 Thus,	 at	 least	 some	 forms	 of	 monogenic	 SLE	 meet	 the	 definition	 of
autoinflammatory	disorders	that	are	caused	by	dysregulation	of	innate	immune	responses	[16,17]	(Fig.	2).
Autosomal	recessive	loss-of-function	mutations	in	upstream	components	of	the	classical	complement	pathway,	namely,	C1q,	C1r,	C1s,	C2,	C4A	and	C4B,	result	in	lupus-like	phenotypes	in	a	large	subset	of	affected	individuals








extracellular	chromatin,	autoantibody	production	and	subsequently	 lupus-like	disease	 [14,23–26].	Recently,	 rare	 familial	 cases	of	SLE	were	associated	with	autosomal	 recessive	mutations	 in	DNASE1L3	 (a	homologue	of	DNAse1),
resulting	in	entirely	abrogated	nuclease	activity,	extracellular	accumulation	of	DNA,	autoantibody	production,	complement	consumption	and	early-onset	SLE	[23,27].
Autosomal	dominant	mutations	 in	TREX1,	 encoding	 for	 the	3′-5'exonuclease	Trex1,	 cause	 familial	 chilblain	 lupus	 (FChL).	Clinical	 characteristics	 of	FChL	 include	Raynaud's	phenomenon,	painful	 and	 sometimes	ulcerating
chilblain	lesions.	First	symptoms	may	manifest	early	in	childhood,	and	up	to	20%	of	patients	with	FChL	progress	to	full-blown	SLE	[28–30].	In	FChL,	loss	of	function	of	Trex1	causes	cytoplasmic	accumulation	of	nucleic	acids	(single-





Taken	 together,	 a	 relatively	 small	number	of	 currently	known	gene	defects	 cause	monogenic	SLE	or	SLE-like	disease.	Mendelian	 forms	of	SLE	are	usually	 characterised	by	a	positive	 family	history,	 early	disease-onset	 in
childhood,	relatively	equal	gender	distribution,	severe	and	sometimes	not	‘classical’	symptoms	and	poor	response	to	‘standard’	treatment.
Risk	alleles






























risk	 alleles	 affect	 lymphocyte	 activation,	 TLR	 and	 type	 I	 interferon	 pathways,	 and	 immune	 complex	 processing	 (Table	 2).	 An	 all-inclusive	 discussion	 of	 genomic	 variants	 in	 SLE	 is	 beyond	 the	 scope	 of	 this	manuscript,	 but	 two
susceptibility	mechanisms	should	be	mentioned.























including	contact	with	 infectious	agents	 and	oxidative	 stress.	 It	 involves	 the	extrusion	of	 chromatin	and	other	nuclear,	 cytoplasmic	and	granular	material	 to	 the	extracellular	 compartment.	Neutrophil	NETs	 contain	 inflammatory
cytokines,	antimicrobial	peptides,	enzymes	and	nucleosomes,	which	represent	key	autoantigens	in	SLE	[71–74].	Furthermore,	neutrophil	NETs	contribute	to	the	expression	of	type	I	interferons	by	plasmacytoid	dendritic	cells	(pDCs)
through	the	activation	of	TLR9.	In	turn,	type	I	interferons	prime	neutrophils	for	NETosis,	which	suggests	a	positive	feedback	loop	that	increases	inflammation	and	tissue	damage	in	SLE	[15,75,76].

















Although	 SLE	 is	 a	 highly	 heterogeneous	 disease,	 most	 patients	 with	 SLE	 exhibit	B	 cell	 activation	 and	 high	 titres	 of	 autoantibodies	 directed	 against	 nuclear	 antigens.	 Autoantibody	 production	 may	 be	 genetically
predetermined	and/or	triggered	by	the	overabundance	of	extracellular	chromatin	components	(detailed	above)	[4,15,16,59,100].	Furthermore,	B	cell	tolerance	can	also	be	breached	by	the	exposure	to	cytokines	(including	the	B	cell
promoting	factors	BAFF/BLyS)	[101,102].	Indeed,	studies	in	humans	have	demonstrated	both	acquired	environmental	and	heritable	genetic	contributions	to	autoreactivity	of	B	cells	with	gradually	increasing	autoreactive	capacities	of	B























































As	mentioned	 above,	 altered	 expression	 and	 activation	 of	 protein	 kinases	 (CaMK4,	SYK,	 etc.)	 and	 transcription	 factors	 (CREMα,	 Stat	 family	 transcription	 factors)	 promise	 potential	 as	 therapeutic	 targets	 in	SLE.	 Indeed,
inhibitors	of	Janus	kinases	(JAK),	Stat	phosphorylation	and	SYK	kinases	are	already	available	and	are	awaiting	further	pre-clinical	and/or	clinical	testing	[162–164].	In	some	rare	monogenic	forms	of	SLE	or	‘SLE-like’	disease,	small	case
series	and/or	individual	case	reports	already	indicate	beneficial	effects	of	JAK	inhibition	[165–167].
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